We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Baxter International (BAX) Q3 Earnings, Sales Top; View Up
Read MoreHide Full Article
Baxter International Inc. (BAX - Free Report) reported third-quarter 2016 adjusted earnings of 56 cents per share, which surpassed the Zacks Consensus Estimate by 12 cents and were well above the year-ago figure of 41 cents.
The company posted sales of $2,558 million, beating the Zacks Consensus Estimate for revenues of $2,545 million. At constant currency (cc), revenues increased 4% on a year-over-year basis.
U.S. sales were up 6% on a year-over-year basis to $1.1 billion. International sales increased 3% at cc to $1.5 billion. Adjusting for the impact of foreign exchange and increased competition for the company’s cyclophosphamide , and 2015 PROTOPAM orders, Baxter’s sales were up 12% in the domestic market. Internationally, sales increased 6% in the reported quarter.
Hospital products sales improved 3% at cc on a year-over-year basis to $1.6 billion, while Renal products sales increased 6% to $977 million.
Hospital Products sales were driven by solid demand for IV solutions, nutritional therapies, pharmacy injectables and IV access administration sets. Renal products sales were driven by peritoneal dialysis products as well as increased demand globally for continuous renal replacement therapies.
Guidance Raised
Based on the company’s strong performance in the first three quarters of the year, Baxter raised its outlook for the full year. Baxter now expects sales to increase approximately 2% on a reported basis and 4% at cc. Previous sales guidance for reported basis was in the range of 1% to 2% and at cc in the range of 3% to 4%.
Adjusted earnings per share are now anticipated in the range of $1.88 to $1.91, up from the earlier guidance of $1.69 to $1.74.
For the fourth quarter of 2016, Baxter expects sales growth at both reported and cc of approximately 2%. Adjusted earnings are forecast in the range of 49 cents to 52 cents per share.
ABIOMED has a long-term expected earnings growth rate of approximately 26.7%. Notably, the stock represents an impressive one-year return of 35.4%.
AngioDynamics has a long-term expected earnings growth rate of 15.00%. The company posted a solid one-year return of 43.0%.
Glaukos Corporation recorded a stellar one-year return of almost 64.3%. Notably, the company posted a positive surprise in the past four quarters, the average being 110.9%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Baxter International (BAX) Q3 Earnings, Sales Top; View Up
Baxter International Inc. (BAX - Free Report) reported third-quarter 2016 adjusted earnings of 56 cents per share, which surpassed the Zacks Consensus Estimate by 12 cents and were well above the year-ago figure of 41 cents.
The company posted sales of $2,558 million, beating the Zacks Consensus Estimate for revenues of $2,545 million. At constant currency (cc), revenues increased 4% on a year-over-year basis.
U.S. sales were up 6% on a year-over-year basis to $1.1 billion. International sales increased 3% at cc to $1.5 billion. Adjusting for the impact of foreign exchange and increased competition for the company’s cyclophosphamide , and 2015 PROTOPAM orders, Baxter’s sales were up 12% in the domestic market. Internationally, sales increased 6% in the reported quarter.
Hospital products sales improved 3% at cc on a year-over-year basis to $1.6 billion, while Renal products sales increased 6% to $977 million.
Hospital Products sales were driven by solid demand for IV solutions, nutritional therapies, pharmacy injectables and IV access administration sets. Renal products sales were driven by peritoneal dialysis products as well as increased demand globally for continuous renal replacement therapies.
Guidance Raised
Based on the company’s strong performance in the first three quarters of the year, Baxter raised its outlook for the full year. Baxter now expects sales to increase approximately 2% on a reported basis and 4% at cc. Previous sales guidance for reported basis was in the range of 1% to 2% and at cc in the range of 3% to 4%.
Adjusted earnings per share are now anticipated in the range of $1.88 to $1.91, up from the earlier guidance of $1.69 to $1.74.
For the fourth quarter of 2016, Baxter expects sales growth at both reported and cc of approximately 2%. Adjusted earnings are forecast in the range of 49 cents to 52 cents per share.
BAXTER INTL Price, Consensus and EPS Surprise
BAXTER INTL Price, Consensus and EPS Surprise | BAXTER INTL Quote
Zacks Rank & Stocks to Consider
Currently, Baxter has a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader medical sector are ABIOMED Inc. , AngioDynamics Inc. (ANGO - Free Report) and Glaukos Corporation (GKOS - Free Report) . Notably all the companies sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
ABIOMED has a long-term expected earnings growth rate of approximately 26.7%. Notably, the stock represents an impressive one-year return of 35.4%.
AngioDynamics has a long-term expected earnings growth rate of 15.00%. The company posted a solid one-year return of 43.0%.
Glaukos Corporation recorded a stellar one-year return of almost 64.3%. Notably, the company posted a positive surprise in the past four quarters, the average being 110.9%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>